ARTICLE | Clinical News
Milatuzumab-doxorubicin conjugate: Phase I/II started
June 21, 2010 7:00 AM UTC
Immunomedics began an open-label, U.S. Phase I/II trial to evaluate 4 dose levels of IV milatuzumab conjugated with doxorubicin for up to 8 cycles in groups of 3-6 patients. The company plans to enro...